164 related articles for article (PubMed ID: 33893839)
1. Application of circulating genetically abnormal cells in the diagnosis of early-stage lung cancer.
Qiu X; Zhang H; Zhao Y; Zhao J; Wan Y; Li D; Yao Z; Lin D
J Cancer Res Clin Oncol; 2022 Mar; 148(3):685-695. PubMed ID: 33893839
[TBL] [Abstract][Full Text] [Related]
2. Detection of circulating genetically abnormal cells in peripheral blood for early diagnosis of non-small cell lung cancer.
Liu WR; Zhang B; Chen C; Li Y; Ye X; Tang DJ; Zhang JC; Ma J; Zhou YL; Fan XJ; Yue DS; Li CG; Zhang H; Ma YC; Huo YS; Zhang ZF; He SY; Wang CL
Thorac Cancer; 2020 Nov; 11(11):3234-3242. PubMed ID: 32989915
[TBL] [Abstract][Full Text] [Related]
3. Detection of circulating genetically abnormal cells using 4-color fluorescence in situ hybridization for the early detection of lung cancer.
Feng M; Ye X; Chen B; Zhang J; Lin M; Zhou H; Huang M; Chen Y; Zhu Y; Xiao B; Huang C; Katz RL; Bai C
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2397-2405. PubMed ID: 33547948
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of circulating genetically abnormal cells to support computed tomography for benign and malignant pulmonary nodules.
Yang H; Chen H; Zhang G; Li H; Ni R; Yu Y; Zhang Y; Wu Y; Liu H
BMC Cancer; 2022 Apr; 22(1):382. PubMed ID: 35397524
[TBL] [Abstract][Full Text] [Related]
5. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
[TBL] [Abstract][Full Text] [Related]
6. Multiplex PCR-based detection of circulating tumor cells in lung cancer patients using CK19, PTHrP, and LUNX specific primers.
Katseli A; Maragos H; Nezos A; Syrigos K; Koutsilieris M
Clin Lung Cancer; 2013 Sep; 14(5):513-20. PubMed ID: 23810363
[TBL] [Abstract][Full Text] [Related]
7. Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis.
Yang J; Jiao S; Kang J; Li R; Zhang G
Int J Clin Exp Pathol; 2015; 8(11):14959-64. PubMed ID: 26823828
[TBL] [Abstract][Full Text] [Related]
8. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
[TBL] [Abstract][Full Text] [Related]
9. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
[TBL] [Abstract][Full Text] [Related]
10. Progress and prospects of early detection in lung cancer.
Blandin Knight S; Crosbie PA; Balata H; Chudziak J; Hussell T; Dive C
Open Biol; 2017 Sep; 7(9):. PubMed ID: 28878044
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer.
Li Y; Tian X; Gao L; Jiang X; Fu R; Zhang T; Ren T; Hu P; Wu Y; Zhao P; Yang D
Cancer Med; 2019 Jul; 8(8):3782-3792. PubMed ID: 31132233
[TBL] [Abstract][Full Text] [Related]
12. A Highly Efficient Gene Expression Programming (GEP) Model for Auxiliary Diagnosis of Small Cell Lung Cancer.
Yu Z; Lu H; Si H; Liu S; Li X; Gao C; Cui L; Li C; Yang X; Yao X
PLoS One; 2015; 10(5):e0125517. PubMed ID: 25996920
[TBL] [Abstract][Full Text] [Related]
13. CTAPIII/CXCL7: a novel biomarker for early diagnosis of lung cancer.
Du Q; Li E; Liu Y; Xie W; Huang C; Song J; Zhang W; Zheng Y; Wang H; Wang Q
Cancer Med; 2018 Feb; 7(2):325-335. PubMed ID: 29356357
[TBL] [Abstract][Full Text] [Related]
14. The Application Value of Serum HE4 in the Diagnosis of Lung Cancer.
Wang Y; Wang Z; Ding Y; Sun F; Ding X
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2405-2407. PubMed ID: 31450913
[TBL] [Abstract][Full Text] [Related]
15. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR-Based Method as a Diagnostic Biomarker for Non-Small-Cell Lung Cancer.
Chen X; Zhou F; Li X; Yang G; Zhang L; Ren S; Zhao C; Deng Q; Li W; Gao G; Li A; Zhou C
J Thorac Oncol; 2015 Aug; 10(8):1163-71. PubMed ID: 26200270
[TBL] [Abstract][Full Text] [Related]
16. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients.
Powrózek T; Krawczyk P; Nicoś M; Kuźnar-Kamińska B; Batura-Gabryel H; Milanowski J
Clin Transl Oncol; 2016 Apr; 18(4):398-404. PubMed ID: 26311076
[TBL] [Abstract][Full Text] [Related]
17. Plasma miR-92a-2 as a biomarker for small cell lung cancer.
Yu Y; Zuo J; Tan Q; Zar Thin K; Li P; Zhu M; Yu M; Fu Z; Liang C; Tu J
Cancer Biomark; 2017; 18(3):319-327. PubMed ID: 28106539
[TBL] [Abstract][Full Text] [Related]
18. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer.
Li J; Liao Y; Ran Y; Wang G; Wu W; Qiu Y; Liu J; Wen N; Jing T; Wang H; Zhang S
BMC Pulm Med; 2020 Oct; 20(1):274. PubMed ID: 33081780
[TBL] [Abstract][Full Text] [Related]
20. [The value of circulating tumor cells detected by chromosome centromere probe identification in diagnosis of non-small cell lung cancer].
Shen Q; Shen LS; Chen Q; Zhou JY; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2018 Oct; 41(10):772-777. PubMed ID: 30347548
[No Abstract] [Full Text] [Related]
[Next] [New Search]
